Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Dec;34(45):3475-7.
doi: 10.1093/eurheartj/eht158. Epub 2013 May 10.

Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity

Luminita H Pojoga  1 , Rene Baudrand, Gail K Adler
Affiliations
Editorial

Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity

Luminita H Pojoga et al. Eur Heart J. 2013 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential mechanisms for increased MR activation in obesity include: 1) adipocyte production of aldosterone and aldosterone secretagogues; 2) increased MR; and 3) alterations in MR-interacting proteins (e.g. Rac1, AT1R, angiotensin II receptor type 1; EGFR, epidermal growth factor receptor; LSD-1, lysine-specific demethylase 1).
Figure 2
Figure 2
MR-mediated effects in endothelium, vascular smooth muscle and perivascular adipose tissue may contribute to vascular dysfunction and injury in obesity. NO, nitric oxide; ICAM, intercellular adhesion molecule.
See this image and copyright information in PMC

Comment on

References

    1. Campia U, Tesauro M, Cardillo C. Human obesity and endothelium-dependent responsiveness. Br J Pharmacol. 2012;165:561–573. - PMC - PubMed
    1. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautiere K, Collet JP, Beygui F, Hennache B, Ennezat PV, Juthier F, Richard F, Dallongeville J, Hillaert MA, Doevendans PA, Jude B, Bertrand M, Montalescot G, Van Belle E. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191–202. - PubMed
    1. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep. 2010;12:252–257. - PMC - PubMed
    1. Calhoun DA, Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010;28:517–527. - PMC - PubMed
    1. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363–5373. - PubMed

MeSH terms